Promedior appoints Elizabeth Trehu CMO
This article was originally published in Scrip
Promedior, a clinical stage biotech company developing novel biologic therapeutics for the treatment of fibrosis, has appointed Dr Elizabeth Trehu chief medical officer. Dr Trehu was most recently vice-president of product development and medical affairs at Infinity Pharmaceuticals, and previously spent four years at Genzyme.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.